Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Glucagon-like peptide-2 (GLP-2) is a 33-amino acid proglucagon-derived peptide released by enteroendocrine L-cells of the distal small intestine and colon. Within experimental gastroenterology, GLP-2 has become a reference tool for probing how the intestinal epithelium grows, repairs itself, and regulates its barrier. GLP-2 TZ is a structurally stabilized GLP-2 receptor agonist used in laboratory settings to interrogate these same pathways with a longer signaling window than the native peptide provides.
This article surveys how GLP-2 TZ is investigated in intestinal-barrier and mucosal research models. It focuses on the GLP-2 receptor (GLP-2R) as the molecular target, the indirect mediators that relay the signal to the epithelium, and the preclinical model systems in which barrier integrity, permeability, and epithelial proliferation are measured. Every description below concerns in-vitro and animal research only; this material is research use only, not for human consumption.
What Is GLP-2 TZ?
GLP-2 belongs to the proglucagon family, a group that also includes glucagon and glucagon-like peptide-1. In enteroendocrine L-cells, the proglucagon precursor is cleaved by prohormone convertase to release GLP-2 alongside its better-studied sibling. The compound supplied as GLP-2 TZ is a stabilized analog of this 33-amino acid sequence, prepared for laboratory investigation of the GLP-2 signaling axis rather than for any applied use.
Structure and Stability
Native GLP-2 is highly labile in circulation because dipeptidyl peptidase-4 (DPP-4) cleaves the peptide after its position-2 alanine, generating an inactive fragment within minutes. GLP-2 TZ incorporates a single substitution near the N-terminus that is studied for its resistance to DPP-4 hydrolysis. In experimental preparations, this modification is associated with a longer functional signaling window, which makes the analog convenient for time-course and repeated-exposure studies where native GLP-2 would degrade too quickly to observe sustained receptor activation.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported value |
|---|---|
| Designation | GLP-2 TZ |
| Peptide class | GLP-2 receptor agonist (proglucagon-derived peptide analog) |
| Parent peptide | Glucagon-like peptide-2 (GLP-2) |
| Sequence length | 33 amino acids |
| Approximate molecular weight | Roughly 3.75 kDa (about 3752 Da) |
| Molecular target | GLP-2 receptor (GLP-2R), a class B GPCR |
| Notable modification | N-terminal substitution studied for DPP-4 resistance |
The GLP-2 Receptor and Intestinal Signaling
The GLP-2 receptor (GLP-2R) is a class B G-protein-coupled receptor coupled primarily to the cAMP and protein kinase A pathway. A defining feature of GLP-2 biology, and a recurring theme in mechanistic research, is that GLP-2R is not expressed on the absorptive enterocytes that form the barrier itself. Instead, receptor expression localizes to subepithelial myofibroblasts, enteric neurons, and subsets of enteroendocrine cells. GLP-2 TZ is therefore studied as an indirect trophic signal: receptor activation on these accessory cells is investigated for its capacity to trigger release of downstream mediators that in turn act on the epithelium.
Downstream Mediators
Preclinical work has linked GLP-2R activation to several paracrine effectors, including insulin-like growth factor-1 (IGF-1), IGF-2, keratinocyte growth factor (KGF, also called FGF-7), and ligands of the ErbB and EGF receptor network. Nitric oxide and vasoactive intestinal peptide (VIP) have been implicated in the mesenteric blood-flow responses recorded in animal models. Because these mediators converge on crypt stem and progenitor cells, researchers use GLP-2 TZ to interrogate how a single receptor signal is relayed into coordinated epithelial proliferation and reduced enterocyte apoptosis.
Intestinal Barrier and Mucosal Research
The intestinal barrier is a selectively permeable interface built from a single layer of epithelial cells joined by tight junctions. Its integrity is the central readout in most GLP-2 TZ barrier studies. Investigators quantify barrier function through transepithelial electrical resistance (TEER) in cultured monolayers, flux of inert tracers such as FITC-dextran, mannitol, or lactulose across the epithelium, and the expression or localization of tight-junction proteins including claudins, occludin, and zonula occludens-1 (ZO-1).
Barrier and Growth Endpoints
In animal and organoid systems, GLP-2R agonism is investigated for its association with greater villus height, deeper crypts, increased mucosal mass, and shifts in the crypt proliferation-to-apoptosis balance. These structural endpoints are typically paired with functional permeability measurements so that changes in tissue mass can be related to changes in barrier tightness. Proliferation markers such as Ki-67 staining and bromodeoxyuridine (BrdU) incorporation are common companions to the barrier assays.
Models of Mucosal Stress
GLP-2 TZ is frequently applied in models where the mucosa is deliberately challenged. These include intestinal resection paradigms that mimic short-bowel physiology, parenteral-nutrition models associated with mucosal atrophy, chemotherapy- and radiation-induced mucositis, dextran sulfate sodium (DSS) colitis, and ischemia-reperfusion injury. Across these systems, the shared research question is whether GLP-2R activation correlates with preserved barrier function and faster epithelial recovery. Such observations are interpreted strictly within each model and are not evidence of any human outcome.
Comparative Attributes and Research Handling
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Native GLP-2 | GLP-2 TZ |
|---|---|---|
| Sequence length | 33 amino acids | 33 amino acids |
| Approximate molecular weight | Roughly 3.76 kDa | Roughly 3.75 kDa |
| Position-2 residue | Alanine | Substituted (studied for DPP-4 resistance) |
| DPP-4 susceptibility | Rapidly cleaved | Reduced cleavage (reported) |
| Reported half-life in models | Minutes | Extended relative to native |
| Primary research target | GLP-2R | GLP-2R |
Reconstitution and Storage
GLP-2 TZ is typically supplied as a lyophilized powder that is reconstituted with bacteriostatic water for in-vitro work. As a worked example, adding 2 mL of bacteriostatic water to a 10 mg vial yields a 5 mg/mL stock. Like most peptides, it is handled cold, protected from repeated freeze-thaw cycles, and aliquoted to preserve stability; consult the linked bacteriostatic water guide for general reconstitution theory rather than repeating it here.
Purity and Documentation
Meaningful barrier data depend on well-characterized material. A batch-specific certificate of analysis reports identity and purity by HPLC and mass spectrometry, and learning to read those figures is covered in the COA and purity guide. Laboratories comparing vendors can also review the supplier-vetting checklist. GLP-2 TZ sits within the broader GLP and metabolic research family alongside GLP-1 SM, and the two are sometimes studied in parallel for their distinct proglucagon-derived targets.
Frequently Asked Questions
What is GLP-2 TZ?
GLP-2 TZ is a stabilized 33-amino acid analog of glucagon-like peptide-2, a proglucagon-derived peptide. It is supplied for research use only, not for human consumption, and is studied as an agonist of the GLP-2 receptor in intestinal models.
What does GLP-2 do to the intestinal barrier in research?
In preclinical models, GLP-2 receptor activation is investigated for its association with epithelial proliferation, tight-junction regulation, and reduced permeability. Researchers measure these endpoints with tools such as TEER, tracer flux, and staining for claudins and ZO-1.
How does GLP-2 TZ differ from native GLP-2?
Native GLP-2 is rapidly cleaved by DPP-4 at its position-2 alanine. GLP-2 TZ carries an N-terminal substitution studied for resistance to that enzyme, giving a longer signaling window that is convenient for time-course experiments.
Does GLP-2 act directly on intestinal cells?
Generally no. The GLP-2 receptor is expressed mainly on subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells rather than on absorptive enterocytes, so GLP-2 TZ is studied as an indirect signal that works through mediators such as IGF-1 and KGF.
What is the molecular weight of GLP-2?
GLP-2 and its analogs are 33-amino acid peptides with an approximate molecular weight near 3.75 kDa. The exact mass varies slightly with sequence modifications and is confirmed by mass spectrometry on the certificate of analysis.
How is GLP-2 TZ handled in the laboratory?
It is generally reconstituted from lyophilized powder with bacteriostatic water, kept cold, protected from repeated freeze-thaw cycles, and stored as aliquots. All handling is for in-vitro and animal research only.
References and Further Reading
- Drucker DJ and colleagues (University of Toronto). Foundational research describing the intestinotrophic actions of GLP-2. PubMed: glp-2 intestinal growth
- GLP-2 receptor expression and signaling in the gut. PubMed: glp-2 receptor signaling
- GLP-2 and intestinal barrier permeability in preclinical models. PubMed: glp-2 intestinal permeability
- GLP-2 and tight-junction protein regulation. PubMed: glp-2 tight junction
- GLP-2 in intestinal adaptation and resection models. PubMed: glp-2 intestinal adaptation
- DPP-4-resistant GLP-2 analogs and peptide stability. PubMed: glp-2 analog dipeptidyl peptidase
- GLP-2 and mucosal epithelial proliferation. PubMed: glp-2 epithelial proliferation
